Gabapentin Treatment for Alcohol Dependence—Reply

Mason, Barbara J.; Goodell, Vivian; Shadan, Farhad F.

doi:10.1001/jamainternmed.2014.1591

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, we found that the rate of SUD was over 4 times higher among individuals who were prescribed gabapentin. While this finding is consistent with off-label use as a treatment for SUD, [11][12][13][14][15][16][17] it may also be a reflection of prescriber reluctance to use opioids for pain treatment in individuals with a history of SUD. 32 Interestingly, the state-year prevalence of gabapentin prescribing observed in this commercially insured population does not align with the states that have taken regulatory actions to increase gabapentin monitoring.…”

Section: Discussionsupporting

confidence: 62%

“…1 Originally approved by the U.S. Food and Drug Administration (FDA) in 1993, gabapentin was perceived to have a low abuse potential and was therefore approved as a nonscheduled medication. 1 Due, in part, to its favorable safety profile, gabapentin has become a prevalent off-label option for a variety of medical conditions, including other neuropathic pain conditions, [3][4] hot flashes, 5,6 postoperative nausea/vomiting, 7,8 postoperative pain, 9,10 alcohol dependence/withdrawal, 11,12 and other substance use disorders (SUD), [13][14][15][16][17] with estimates of off-label prescribing as high as 95%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016

Pauly

Delcher

Slavova

et al. 2020

JMCP

View full text Add to dashboard Cite

BACKGROUND:Gabapentin is prescribed for a variety of conditions and is often used off label. It is important to understand the prevalence of gabapentin prescribing and the characteristics of individuals who are prescribed gabapentin, given increasing concern regarding its potential for misuse.OBJECTIVES: To (a) examine state-and region-level prevalence and trends in gabapentin prescribing from 2009 to 2016 and (b) characterize demographic and clinical characteristics of individuals prescribed gabapentin in a nationwide population of commercially insured adults. METHODS:This retrospective, longitudinal study examined trends in gabapentin prescribing from 2009 to 2016. The study population included individuals aged 18-64 years who were enrolled in a commercial insurance plan at any point from 2009 to 2016. Individuals who were prescribed gabapentin were defined as beneficiaries with at least 1 gabapentin prescription claim

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016

Pauly

Delcher

Slavova

et al. 2020

JMCP

View full text Add to dashboard Cite

show abstract

From gene networks to drugs: systems pharmacology approaches for AUD

2018

View full text Add to dashboard Cite

The alcohol research field has amassed an impressive number of gene expression datasets spanning key brain areas for addiction, species (humans as well as multiple animal models), and stages in the addiction cycle (binge/intoxication, withdrawal/negative effect, and preoccupation/anticipation). These data have improved our understanding of the molecular adaptations that eventually lead to dysregulation of brain function and the chronic, relapsing disorder of addiction. Identification of new medications to treat alcohol use disorder (AUD) will likely benefit from the integration of genetic, genomic, and behavioral information included in these important datasets. Systems pharmacology considers drug effects as the outcome of the complex network of interactions a drug has rather than a single drug-molecule interaction. Computational strategies based on this principle that integrate gene expression signatures of pharmaceuticals and disease states have shown promise for identifying treatments that ameliorate disease symptoms (called in silico gene mapping or connectivity mapping). In this review, we suggest that gene expression profiling for in silico mapping is critical to improve drug repurposing and discovery for AUD and other psychiatric illnesses. We highlight studies that successfully apply gene mapping computational approaches to identify or repurpose pharmaceutical treatments for psychiatric illnesses. Furthermore, we address important challenges that must be overcome to maximize the potential of these strategies to translate to the clinic and improve healthcare outcomes.

show abstract

Needed Relapse-Prevention Research on Novel Framework (ASPIRE Model) for Substance Use Disorders Treatment

Ghitza

2015

Front. Psychiatry

View full text Add to dashboard Cite

Gabapentin Treatment for Alcohol Dependence—Reply

Cited by 3 publications

References 3 publications

Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016

Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016

From gene networks to drugs: systems pharmacology approaches for AUD

Needed Relapse-Prevention Research on Novel Framework (ASPIRE Model) for Substance Use Disorders Treatment

Contact Info

Product

Resources

About